Abstract
Heparin and its low molecular weight derivatives are clinical therapeutics used to treat and prevent blood clots, but are prone to side effects and contamination. Here we describe the design and expedient synthesis of heparin-based glycopolymers that are potent and potentially safer mimetics of heparin. The mimetics exhibited strong activity against proteases in the coagulation cascade and prolonged blood clot times in human plasma with efficacies similar to those of clinical anticoagulants.